Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics (RNA) granted equity inducement awards on September 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan.

Rhea-AI Summary

Atrium Therapeutics (RNA) granted equity inducement awards on September 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan.

The employee received non-qualified stock options for 13,500 shares at an exercise price of $8.95 per share, with 25% vesting on the first anniversary and the remainder vesting in 36 monthly installments thereafter, subject to continued service. The employee also received restricted stock units covering 6,750 shares, with 25% vesting on the first anniversary and the remainder vesting in three annual installments, also subject to continued service. The awards were approved by the Human Capital Management Committee of the board, in accordance with Nasdaq Listing Rule 5635(c)(4).

News Explained

The awards do not fully affect the share count immediately: the 13,500 options and 6,750 restricted stock units vest over time, but vested RSUs and exercised options can add employee-held common shares and reduce existing holders’ ownership percentage.

Market Context

The Aug. 20 inducement-grant announcement was followed by a -2.08% 24-hour move; this announcement a...

Analysis

The Aug. 20 inducement-grant announcement was followed by a -2.08% 24-hour move; this announcement again used the 2026 plan for one newly hired non-executive employee.

Key Figures

Option shares: 13,500 shares Exercise price: $8.95 per share Initial option vesting: 25% +4 more

Option shares

13,500 shares

Non-qualified stock options

Exercise price

$8.95 per share

Option exercise price

Initial option vesting

25%

On the first anniversary of the grant date

Remaining option vesting

36 installments

Substantially equal monthly installments

Restricted stock units

6,750 shares

Aggregate RSUs

Initial RSU vesting

25%

In the first anniversary of the grant date

Remaining RSU vesting

3 installments

Substantially equal annual installments

Historical Context

2 past events · Latest: Aug 20

2 events

1. Aug 20

   Inducement grants

   24h Move

   -2.1%

   Equity awards to one newly hired employee under the 2026 inducement plan

2. Jul 20

   Inducement grants

   24h Move

   +4.5%

   Equity awards to one newly hired employee under the 2026 inducement plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4), par value

4 terms

non-qualified stock options financial

"non-qualified stock options to purchase 13,500 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"restricted stock units for an aggregate of 6,750 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

par value financial

"common stock, par value $0.001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

The employee received, in the aggregate, non-qualified stock options to purchase 13,500 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $8.95 per share, the closing price of the Company's common stock as reported by Nasdaq on the last trading day preceding the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 6,750 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."

All of the above-described Awards were granted pursuant to the 2026 Inducement Plan. The Awards were approved by the Human Capital Management Committee of the Company's Board of Directors, which is comprised solely of independent directors, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies. For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302885162.html

SOURCE Atrium Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What plan were the inducement awards for the new Atrium Therapeutics employee granted under?

The stock options and restricted stock units were granted under Atrium Therapeutics' 2026 Employment Inducement Incentive Award Plan, described as the 2026 Inducement Plan.

How do the stock options granted to the new employee vest?

The non-qualified stock options for 13,500 shares vest with 25% becoming exercisable on the first anniversary of the grant date, and the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter, subject to the employee's continued service through each vesting date.

What is the vesting schedule for the restricted stock units granted by Atrium Therapeutics?

The restricted stock units covering 6,750 shares vest with 25% on the first anniversary of the grant date, and the remaining underlying shares vesting in three substantially equal annual installments, subject to the employee's continued service through each applicable vesting date.

What was the exercise price of the non-qualified stock options and how was it determined?

The stock options have an exercise price of $8.95 per share, which equals the closing price of Atrium Therapeutics' common stock as reported by Nasdaq on the last trading day preceding the effective date of the grant.

Who approved the inducement awards and under what Nasdaq rule were they granted?

The awards were approved by the Human Capital Management Committee of the board of directors, which is comprised solely of independent directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).